Circulating oxidized LDL forms complexes with β 2-glycoprotein I: Implication as an atherogenic autoantigen

Journal of Lipid Research

Volumn 44, Issue 4, 2003, Pages 716-726

  Kobayashi, Kazuko ^a   Kishi, Makoto ^a,b   Atsumi, Tatsuya ^c   Bertolaccini, Maria L ^d   Makino, Hirofumi ^a   Sakairi, Nobuo ^e   Yamamoto, Itaru ^b   Yasuda, Tatsuji ^a   Khamashta, Munther A ^d   Hughes, Graham R V ^d   Koike, Takao ^c   Voelker, Dennis R ^f   Matsuura, Eiji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e HOKKAIDO UNIVERSITY   (Japan)

^f NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Antiphospholipid syndrome; Arterial thrombosis; Autoantibody

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; CARBOXYL GROUP; CHOLESTEROL; IMMUNOGLOBULIN G ANTIBODY; KETONE; LIGAND; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXYSTEROL;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANTIGEN ANTIBODY COMPLEX; ANTIGEN RECOGNITION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; ATHEROGENESIS; AUTOIMMUNITY; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOCIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN STABILITY; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; TEMPERATURE DEPENDENCE; TIME;

EID: 10744226230     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200329-JLR200     Document Type: Article

References (62)

1. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
2. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272: 20963-20966.
3. Heinecke, J. W. 1997. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr. Opin. Lipidol. 8: 268-274.
4. Esterbauer, H., R. J. Schaur, and H. Zollner. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11: 81-128.
5. McIntyre, T. M., G. A. Zimmerman, and S. M. Prescott. 1999. Biologically active oxidized phospholipids. J. Biol. Chem. 274: 25189-25192.
6. Stremler, K. E., D. M. Stafforini, S. M. Prescott, and T. M. McIntyre. 1991. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J. Biol. Chem. 266: 11095-11103.
7. Schlame, M., R. Haupt, I. Wiswedel, W. J. Kox, and B. Rustow. 1996. Identification of short-chain oxidized phosphatidylcholine in human plasma. J. Lipid Res. 37: 2608-2615.
8. Frey, B., R. Haupt, S. Alms, G. Holzmann, T. Konig, H. Kern, W. Kox, B. Rustow, and M. Schlame. 2000. Increase in fragmented phosphatidylcholine in blood plasma by oxidative stress. J. Lipid Res. 41: 1145-1153.
9. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Hörkkö, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, G. Subbanagounder, A. M. Fogelman, and J. A. Berliner. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
10. Subbanagounder, G., N. Leitinger, D. C. Schwenke, J. W. Wong, H. Lee, C. Rizza, A. D. Watson, K. F. Faull, A. M. Fogelman, and J. A. Berliner. 2000. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler. Thromb. Vasc. Biol. 20: 2248-2254.
11. Esterbauer, H., G. Jurgens, O. Quehenberger, and E. Koller. 1987. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J. Lipid Res. 28: 495-509.
12. Palinski, W., M. E. Rosenfeld, S. Ylä-Herttuala, G. C. Gurtner, S. S. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
13. Virella, G., I. Virella, R. B. Leman, M. B. Pryor, and M. F. Lopez-Virella. 1993. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin Lab. Res. 23: 95-101.
14. Bergmark, C., R. Wu, U. de Faire, A. K. Lefvert, and J. Swedenborg. 1995. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15: 441-445.
15. Maggi, E., R. Chiesa, G. Melissano, R. Castellano, D. Astore, A. Grossi, G. Finardi, and G. Bellomo. 1994. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14: 1892-1899.
16. Lehtimäki, T., S. Lehtinen, T. Solakivi, M. Nikkilä, O. Jaakkola, H. Jokela, S. Ylä-Herttuala, J. S. Luoma, T. Koivula, and T. Nikkari. 1999. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 19: 23-27.
17. Bui, M. N., M. N. Sack, G. Moutsatsos, D. Y. Lu, P. Katz, R. McCown, J. A. Breall, and C. E. Rackley. 1996. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am. Heart J. 131: 663-667.
18. Palinski, W., S. Hörkkö, E. Miller, U. P. Steinbrecher, H. C. Powell, L. K. Curtiss, and J. L. Witztum. 1996. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 98: 800-814.
19. Hörkkö, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, W. Palinski, and J. L. Witztum. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
20. Friedman, P., S. Hörkkö, D. Steinberg, J. L. Witztum, and E. A. Dennis. 2002. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277: 7010-7020.
21. Hughes, G. R. V., E. N. Harris, and A. E. Gharavi. 1986. The anticardiolipin syndrome. J. Rheumatol. 13: 486-489.
22. Harris, E. N., A. E. Gharavi, M. L. Boey, B. M. Patel, C. G. Mackworth-Young, S. Loizou, and G. R. V. Hughes. 1983. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 2: 1211-1214.
23. McNeil, H. P., R. J. Simpson, C. N. Chesterman, and S. A. Krilis. 1990. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc. Natl. Acad. Sci. USA. 87: 4120-4124.
24. Galli, M., P. Comfurius, C. Maassen, H. C. Hemker, M. H. de Baets, P. J. C. Van Breda-Vriesman, T. Barbui, R. F. A. Zwaal, and E. M. Bevers. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335: 1544-1547.
25. Matsuura, E., Y. Igarashi, M. Fujimoto, K. Ichikawa, and T. Koike. 1990. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 336: 177-178.
26. Wurm, H. 1984. β2-glycoprotein-I (apolipoprotein H) interactions with phospholipid vesicles. Int. J. Biochem. 16: 511-515.
27. Polz, E. 1988. Isolation of a specific lipid-binding protein from human serum by affinity chromatography using heparin-Sepharose. In. Provides of Biological Fluids. H. Peeters, editor. Pergamon Press, Oxford, 817-820.
28. Vazquez-Mellado, J., L. Llorente, Y. Richaud-Patin, and D. Alarcon-Segovia. 1994. Exposure of anionic phospholipids upon platelet activation permits binding of β2-glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J. Autoimmun. 7: 335-348.
29. Price, B. E., J. Rauch, M. A. Shia, M. T. Walsh, W. Lieberthal, H. M. Gilligan, T. O'Laughlin, J. S. Koh, and J. S. Levine. 1996. Antiphospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β2-glycoprotein I-dependent manner. J. Immunol. 157: 2201-2208.
30. Matsuura, E., Y. Igarashi, T. Yasuda, D. A. Triplett, and T. Koike. 1994. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J. Exp. Med. 179: 457-462.
31. Igarashi, M., E. Matsuura, Y. Igarashi, H. Nagae, K. Ichikawa, D. A. Triplett, and T. Koike. 1996. Human β2-glycoprotein I as an anticardiolipin cofactor determined using deleted mutants expressed by a baculovirus system. Blood. 87: 3262-3270.
32. Chamley, L. W., A. M. Duncalf, B. Konarkowska, M. D. Mitchell, and P. M. Johnson. 1999. Conformationally altered β2-glycoprotein I is the antigen for anti-cardiolipin autoantibodies. Clin. Exp. Immunol. 115: 571-576.
33. Wang, S. X., Y. T. Sun, and S. F. Sui. 2000. Membrane-induced conformational change in human apolipoprotein H. Biochem. J. 348: 103-106.
34. Roubey, R. A. S., R. A. Eisenberg, M. F. Harper, and J. B. Winfield. 1995. Anticardiolipin autoantibodies recognize β2-glycoprotein I structure in the absence of phospholipid. Importance of Ag density and bivalent binding. J. Immunol. 154: 954-960.
35. Tincani, A., L. Spatola, E. Prati, F. Allegri, P. Ferremi, R. Cattaneo, P. Meroni, and G. Balestrieri. 1996. The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution. J. Immunol. 157: 5732-5738.
36. Sheng, Y., D.A. Kandiah, and S.A. Krilis. 1998. Anti-β 2-glycoprotein I autoantibodies from patients with the " antiphospholipid" syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity. J. Immunol. 161: 2038-2043.
37. Lutters, B. C. H., J. C. M. Meijers, R. H. W. M. Derksen, and J. Arnout. 2001. Dimers of β2-glycoprotein I mimic the in vitro effects of β2-glycoprotein I-anti-β2-glycoprotein I antibody complexes. J. Biol. Chem. 276: 3060-3067.
38. Bouma, B., P. G. de Groot, J. M. H. van den Elsen, R. B. G. Ravelli, A. Schouten, M. J. A. Simmelink, R. H. W. M. Derksen, J. Kroon, and P. Gros. 1999. Adhesion mechanism of human β2-glycoprotein I to phospholipids based on its crystal structure. EMBO J. 18: 5166-5174.
39. Hoshino, M., Y. Hagihara, I. Nishii, T. Yamazaki, H. Kato, and Y. Goto. 2000. Identification of the phospholipid-binding site of human β2-glycoprotein I domain V by heteronuclear magnetic resonance. J. Mol. Biol. 304: 927-939.
40. Hong, D. P., Y. Hagihara, H. Kato, and Y. Goto. 2001. Flexible loop of β2-glycoprotein I domain V specifically interacts with hydrophobic ligands. Biochemistry. 40: 8092-8100.
41. Vaarala, O., G. Alfthan, M. Jauhiainen, M. Leirisalo-Repo, K. Aho, and T. Palosuo. 1993. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 341: 923-925.
42. Tinahones, F. J., M. J., Cuadrado, M. A. Khamashta, F. Mujic, J. M. Gomez-Zumaquero, E. Collantes, and G. R. V. Hughes. 1998. Lack of cross reaction between antibodies to β2-glycoprotein-I and oxidized low-density lipoprotein in patients with antiphospholipid syndrome. Br. J. Rheumatol. 37: 746-749.
43. Romero, F. I., O. Amengual, T. Atsumi, M. A. Khamashta, F. J. Tinahones, and G. R. V. Hughes. 1998. Arterial disease in lupus and secondary antiphospholipid syndrome: Association with anti-β2-glycoprotein I antibodies but not with antibodies against oxidized low-density lipoprotein. Br. J. Rheumatol. 37: 883-888.
44. Hasunuma, Y., E. Matsuura, Z. Makita, T. Katahira, S. Nishi, and T. Koike. 1997. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107: 569-573.
45. Kobayashi, K., E. Matsuura, Q. Liu, J. Furukawa, K. Kaihara, J. Inagaki, T. Atsumi, N. Sakairi, T. Yasuda, D. R. Voelker, and T. Koike. 2001. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J. Lipid Res. 42: 697-709.
46. Liu, Q., K. Kobayashi, J. Furukawa, J. Inagaki, N. Sakairi, A. Iwado, T. Yasuda, T. Koike, D. R. Voelker, and E. Matsuura. ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res. 43: 1486-1495.
47. Wilson, W. A., A. E. Gharavi, T. Koike, M. D. Lockshin, D. W. Branch, J. C. Piette, R. Brey, R. Derksen, E. N. Harris, G. R. V. Hughes, D. A. Triplett, and M. A. Khamashta. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42: 1309-1311.
48. Hashimoto, Y., M. Kawamura, K. Ichikawa, T. Suzuki, T. Sumida, S. Yoshida, E. Matsuura, S. Ikehara, and T. Koike. 1992. Anticardiolipin antibodies in NZW x BXSB FI mice a model of antiphospholipid syndrome. J. Immunol. 149: 1063-1068.
49. Ichikawa, K., M. A. Khamashta, T. Koike, E. Matsuura, and G. R. V. Hughes. 1994. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum. 37: 1453-1461.
50. Matsuura, E., Y. Igarashi, M. Fujimoto, K. Ichikawa, T. Suzuki, T. Sumida, T. Yasuda, and T. Koike. 1992. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J. Immunol. 148: 3885-3891.
51. Havel, R.J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 43: 1345-1353.
52. Ohkawa, H., N. Ohishi, and K. Yagi. 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358.
53. Matsuura, E., J. Inagaki, H. Kasahara, D. Yamamoto, T. Atsumi, K. Kobayashi, K. Kaihara, D. Zhao, K. Ichikawa, A. Tsutsumi, T. Yasuda, D. A. Triplett, and T. Koike. 2000. Proteolytic cleavage of β2-glycoprotein I: reduction of antigenicity and the structural relationship. Int. Immunol. 12: 1183-1192.
54. Hörkkö, S., T. Olee, L. Mo, D. W. Branch, V. L. Woods, Jr., W. Palinski, P. P. Chen, and J. L. Witztum. 2001. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both β2-glycoprotein 1 and oxidized low-density lipoprotein. Circulation. 103: 941-946.
55. Kritharides, L., W. Jessup, J. Gifford, and R. T. Dean. 1993. A method for defining the stages of low-density lipoprotein oxidation by the separation of cholesterol- and cholesteryl ester-oxidation products using HPLC. Anal. Biochem. 213: 79-89.
56. Kamido, H., A. Kuksis, L. Marai, and J. J. Myher. 1995. Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. J. Lipid Res. 36: 1876-1886.
57. Hoppe, G., A. Ravandi, D. Herrera, A. Kuksis, and H. F. Hoff. 1997. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J. Lipid Res. 38: 1347-1360.
58. Virella, G., I. Virella, R. B. Leman, M. B. Pryor, and M. F. Lopez-Virella. 1993. Anti-oxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23: 95-101.
59. Virella, G.,J. M. Kilpatrick, F. Chenais, and H. H. Fudenberg. 1981. Isolation of soluble immune complexes from human serum: combined use of polyethylene glycol precipitation, gel filtration, and affinity chromatography on protein A-sepharose. Meth. Enzymol. 74: 644-663.
60. Mironova, M., G. Virella, I. Virella-Lowell, and M. F. Lopez-Virella. 1997. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85: 73-82.
61. George, J., A. Afek, B. Gilburd, M. Blank, Y. Levy, A. Aron-Maor, H. Levkovitz, A. Shaish, I. Goldberg, J. Kopolovic, D. Harats, and Y. Shoenfeld. 1998. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation. 98: 1108-1115.
62. George, J., D. Harats, B. Gilburd, A. Afek, Y. Levy, J. Schneiderman, I. Barshack, J. Kopolovic, and Y. Shoenfeld. 1999. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 99: 2227-2230.